Ophthalmic implant system for drug delivery
Inventors
Dennewill, James R. • Kahook, Malik Y. • Sussman, Glenn R. • Cable, II, Craig Alan
Assignees
University of Colorado Colorado Springs • Spyglass Pharma Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11903874-B2
Publication Date
2024-02-20
Expiration Date
Abstract
An ophthalmic implant including an intraocular lens (IOL) and at least one drug delivery device. The IOL including an anterior side, a posterior side, a lens, and at least one haptic extending outwardly from the lens and including a first haptic extending from the lens at a first optic-haptic junction. The at least one drug delivery device including a first drug delivery device including a pad and a fixation portion extending from the pad. The pad including at least one therapeutic agent contained therein, an anterior surface, a posterior surface, and a sidewall extending around the pad and between the anterior surface and the posterior surface. The drug delivery device configured for attachment to the IOL via the fixation portion. In an assembled state of the implant, the first drug delivery device is attached to the IOL and the pad overlays the first optic-haptic junction.
Core Innovation
The invention describes an ophthalmic implant system that combines an intraocular lens (IOL) with outwardly extending haptics and a releasably attachable drug delivery device. The IOL includes an anterior side, a posterior side, a lens, and at least one haptic extending outwardly from the lens at an optic-haptic junction. The drug delivery device includes a pad and a fixation portion extending from the pad, where the pad contains at least one therapeutic agent.
In an assembled state, the drug delivery device is attached to the IOL via the fixation portion, and the pad overlays the optic-haptic junction on the anterior side of the IOL. The attachment architecture includes an IOL tab with concave surfaces and a waist, and a drug-device fixation portion with an opening bordered by walls and/or a retaining structure. The pad surface is defined with anterior, posterior, and side surfaces extending around the pad between the anterior and posterior surfaces.
The invention further describes configurations for placement within an eye, including placement in a capsular bag, where the IOL includes an outwardly extending structure comprising a first pair of inwardly facing concave surfaces and an outer surface between the concave surfaces. The fixation portion is configured for attachment to the IOL structure, including geometries such as an opening bordered by walls and/or a through hole configured to receive the structure. The drug delivery pad may include a matrix containing the therapeutic agent, and the agent may elute from the matrix, including embodiments where the fixation portion is devoid of therapeutic agent.
Claims Coverage
The partial claim set includes three independent claims, each centered on an ophthalmic implant that attaches a therapeutic-agent pad to an IOL at an optic-haptic-related interface. Across the independent claims, three main inventive feature groups are present: pad overlaying an optic-haptic junction on the IOL anterior side, engagement of the fixation portion with concave surfaces defining a waist outwardly of the lens, and a capsular bag placement configuration with fixation portion attachment to a concave-surface IOL structure.
Pad overlaying optic-haptic junction on IOL anterior side
An ophthalmic implant comprising an IOL with at least one haptic extending outwardly from the lens at a first optic-haptic junction and a drug delivery device having a pad containing at least one therapeutic agent and a fixation portion; where, in an assembled state, the drug delivery device is attached to the IOL via the fixation portion and the pad overlays the first optic-haptic junction on the anterior side of the IOL.
Fixation portion engaged with pair of concave surfaces defining waist outwardly of the lens
An ophthalmic implant comprising an IOL with at least one haptic extending outwardly from the lens at a first optic-haptic junction and a drug delivery device having a pad containing at least one therapeutic agent and a fixation portion extending from the pad; where, in an assembled state, the fixation portion is engaged with a pair of concave surfaces of the IOL, the pair of concave surfaces defining a waist therebetween and positioned outwardly of the lens.
Capsular bag placement with drug delivery device attached to inwardly facing concave-surface IOL structure
An ophthalmic implant configured for placement within a capsular bag of an eye of a subject, comprising an IOL with at least one structure extending outwardly from the lens, the at least one structure including a first pair of inwardly facing concave surfaces and an outer surface extending between the pair of inwardly facing concave surfaces; and at least one drug delivery device having a pad containing at least one therapeutic agent and a fixation portion extending from the pad, the drug delivery device configured for attachment to the first structure via the fixation portion.
Across the independent claims, coverage centers on attaching a therapeutic-agent pad to an IOL using a fixation portion, with the pad positioned to overlay an optic-haptic junction, and/or with the fixation portion engaged to concave-surface structures that define a waist. One independent claim further constrains the implant to be configured for placement within a capsular bag, with fixation attachment to inwardly facing concave-surface IOL structures.
Stated Advantages
Documented Applications
Treatment of conditions including glaucoma.
Treatment of wet macular degeneration and dry macular degeneration.
Treatment of uveitis.
Treatment for posterior capsular opacification.
Post-op management after cataract surgery.
Interested in licensing this patent?